At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia
In Brief
An observational study evaluating A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment and HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for Exposure During Pregnancy. Completed, enrolled 16 participants across 8 sites in 5 countries.
Detailed Summary
The purpose of this registry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), regarding the course and outcome of pregnancy in women ever treated with HYQVIA. Development of the fetus/infant at birth and for the first 2 years will also be followed.
Study Details
Timeline
Interventions
To be determined by the physician
Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase